GLUE
$16.03
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The comp...
Recent News
Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Tuesday Ahead of US Federal Reserve Meeting
The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.2% and the actively trad
Monte Rosa Therapeutics touts molecular glue pipeline, tees up GFORCE updates and Phase II plans
Monte Rosa Therapeutics (NASDAQ:GLUE) highlighted progress across its molecular glue degrader pipeline during a presentation at the Barclays 28th Annual Global Healthcare Conference, with Chief Medical Officer Filip Janku outlining upcoming clinical milestones in inflammation and immunology (I&I
Monte Rosa Therapeutics (GLUE) Reports Q4 Loss, Misses Revenue Estimates
Monte Rosa Therapeutics (GLUE) delivered earnings and revenue surprises of -17.02% and -72.90%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Monte Rosa Therapeutics: Q4 Earnings Snapshot
BOSTON (AP) — Monte Rosa Therapeutics Inc. GLUE) on Tuesday reported a loss of $46.1 million in its fourth quarter. The Boston-based company said it had a loss of 55 cents per share.
Agenus (AGEN) Q4 Earnings and Revenues Surpass Estimates
Agenus (AGEN) delivered earnings and revenue surprises of +144.27% and +17.54%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?